Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

Bosma, Nicholas A; Warkentin, Matthew T; Gan, Chun Loo; Karim, Safiya; Heng, Daniel Y C; Brenner, Darren R; Lee-Ying, Richard M

Bosma, Nicholas A; Warkentin, Matthew T; Gan, Chun Loo; Karim, Safiya; Heng, Daniel Y C; Brenner, Darren R; Lee-Ying, Richard M.

Afiliación

Bosma NA; Department of Oncology, University of Calgary Tom Baker Cancer Centre, Calgary, AB, Canada.
Warkentin MT; Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, ON, Canada.
Gan CL; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada.
Karim S; Department of Oncology, University of Calgary Tom Baker Cancer Centre, Calgary, AB, Canada.
Heng DYC; Department of Oncology, University of Calgary Tom Baker Cancer Centre, Calgary, AB, Canada.
Brenner DR; Department of Oncology, University of Calgary Tom Baker Cancer Centre, Calgary, AB, Canada.
Lee-Ying RM; Department of Community Health Sciences, University of Calgary Cumming School of Medicine, Calgary, AB, Canada.

Eur Urol Open Sci ; 37: 14-26, 2022 Mar.

Article en En | MEDLINE | ID: mdl-35128482

Palabras clave

Immunotherapy; Network meta-analysis; Renal cell carcinoma; Tyrosine kinase inhibitors

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Tipo de estudio: Clinical_trials / Systematic_reviews Idioma: En Revista: Eur Urol Open Sci Año: 2022 Tipo del documento: Article País de afiliación: Canadá

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google